Viral Interactions with B-cells Contribute to Increased Regulatory T-cells During Chronic HCV Infection
Overview
Microbiology
Affiliations
Hepatitis C virus (HCV) has a propensity to establish chronic infection that is characterized by attenuated virus-specific T-cell responses. Mechanisms leading to T-cell attenuation are poorly understood and likely involve dysfunctional interactions between antigen-presenting cells (APC) and effector/regulatory T-cells. Reports on dendritic cells (DC) have described only minor dysfunction during HCV infection. However, there is a paucity of reports regarding B-cell function, despite clear associations with B-cell-related secondary sequelae. In this study we evaluated the state of B-cells during chronic HCV infection, and observed a diminished ability to respond to mitogenic stimuli, correlating with increased apoptosis. This was in contrast to their ex vivo phenotype, which indicated ongoing chronic activation in vivo. There was a high association of HCV-positive strand RNA with B-cells in a subset of HCV patients. Interestingly, ex-vivo-derived HCV RNA-positive B-cells induced significantly greater proliferation in allogeneic T-cells than in HCV-negative B-cells, correlating with an increased generation of CD4(+)CD25(+)FOXP3(+) regulatory T-cells (Tregs). In-vitro exposure of healthy peripheral blood mononuclear cells (PBMC) to HCV resulted in robust activation of resting B-cells. These HCV-exposed B-cells also showed an enhanced ability to generate Tregs. Our results provide strong evidence for a novel and paradoxical link between HCV-induced enhanced APC function and the generation of Tregs.
Fang Q, Deng Y, Liang R, Mei Y, Hu Z, Wang J Am J Transl Res. 2020; 12(3):889-900.
PMID: 32269721 PMC: 7137049.
Moore T, Messer R, Gonzaga L, Mather J, Carmody A, Bayer W mBio. 2019; 10(1).
PMID: 30670616 PMC: 6343038. DOI: 10.1128/mBio.02578-18.
Pawelczyk A, Kubisa N, Jablonska J, Bukowska-Osko I, Caraballo Cortes K, Fic M Virol J. 2013; 10:346.
PMID: 24279719 PMC: 4222874. DOI: 10.1186/1743-422X-10-346.
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Ayers C, Mendoza J, Sinha S, Cunnusamy K, Greenberg B, Frohman E Clin Immunol. 2013; 147(2):105-19.
PMID: 23578552 PMC: 3634883. DOI: 10.1016/j.clim.2013.02.015.